Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: Results of a 1-year follow-up study from the CERERRA collaboration

Annals of the Rheumatic Diseases

Volumn 71, Issue 3, 2012, Pages 374-377

  Chatzidionysiou, Katerina ^a   Lie, Elisabeth ^b   Nasonov, Evgeny ^c   Lukina, Galina ^c   Hetland, Merete Lund ^d   Tarp, Ulrik ^e   Van Riel, Piet L C M ^f   Nordström, Dan C ^g   Gomez Reino, Juan ^h   Pavelka, Karel ⁱ   Tomsic, Matija ^j   Kvien, Tore K ^b   Van Vollenhoven, Ronald F ^a   Gabay, Cem ^k  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DIAKONHJEMMET HOSPITAL   (Norway)

^c V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^d Mental Health Center Glostrup   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h University Hospital of Santiago de Compostela   (Spain)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^k GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB;

ACUTE HEART INFARCTION; ADULT; ARTICLE; ASPIRATION PNEUMONIA; BRAIN HEMORRHAGE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; EUROPE; FEMALE; FOLLOW UP; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RHEUMATOID ARTHRITIS; STROKE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; TREATMENT OUTCOME;

EID: 84857238587     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200003     Document Type: Article

References (15)

1. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
2. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
3. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010;69:1629-35.
4. Suarez-Almazor M E, Belseck E, Shea B, et al. Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000;2:CD000957.
5. Kalden J R, Schattenkirchner M, Sörensen H, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum 2003;48:1513-20. (Pubitemid 36682358)
6. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159:2542-50.
7. Osiri M, Shea B, Robinson V, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003;1:CD002047.
8. De Stefano R, Frati E, Nargi F, et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexateanti- TNF-alpha. Clin Rheumatol 2010;29:517-24.
9. Henes J C, Schedel J, Kanz L, et al. Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis. Rheumatol Int 2010;30:709-12.
10. Vital E M, Dass S, Rawstron AC, et al. Combination rituximab and leflunomide produces lasting responses in rheumatoid arthritis (Abstract). Ann Rheum Dis 2008;67:90.
11. Buch M H, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909-20.
12. Siemasko K F, Chong AS, Williams JW, et al. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996;61:635-42. (Pubitemid 26073611)
13. Ringshausen I, Oelsner M, Bogner C, et al. The immunomodulatory drug leflunomide inhibits cell cycle progression of B-CLL cells. Leukemia 2008;22:635-8. (Pubitemid 351386736)
14. Menard L, Samuels J, Ng YS, et al. Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis. Arthritis Rheum 2011;63:1237-45.
15. Owczarczyk K, Hellmann M, Fliedner G, et al. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Ann Rheum Dis 2008;67:1648-9.